Skip to main content

Advertisement

Table 2 Comparison of SAR228810 with other clinical anti-amyloid antibodies in neuroprotection assay

From: SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)

% control response (no oAβ42) oAβ42 5 μM oAβ42 + SAR228810 oAβ42 + gantenerumab oAβ42 + BAN-2401
50 μg/ml 150 μg/ml 50 μg/ml 150 μg/ml 50 μg/ml 150 μg/ml
Neurite network (MAP2) 49.84 ± 10.29 86.17 ± 10.25 96.49 ± 0.86 70.57 ± 1.66 82.27 ± 6.70 79.34 ± 0.70 86.78 ± 2.75
p < 0.0001 p < 0.0001 p = 0.0022 p < 0.0001 p = 0.0059 p < 0.0001
Caspase 3/7 activity 291.47 ± 48.73 190.84 ± 39.15 103.42 ± 10.36 388.89 ± 150.02 360.38 ± 123.53 428.48 ± 136.51 355.14 ± 124.57
p = 0.0001 p < 0.0001 NS NS (p = 0.2562) NS (p = 0.8675) NS (p = 0.9995)
  1. Control response without oAβ42 = 100%; data are expressed as medians ± median absolute deviation (MAD); n = 3–7
  2. P values were obtained with a Dunnett‘s test versus oAβ42 after a one-way ANOVA on rank-transformed data
  3. NS not significant, oAβ oligomeric amyloid β